Two-thousand nine is being dubbed “the year of the generic”. Two senators are trying to keep it that way, citing the potential for Pharma (and its branded, patent-extending reformulations) to simply pay off the manufacturers of generics in an effort to halt their production. It is the aim of the Preserve Access to Affordable Generics Act to abolish the so-called “pay-to-delay” actions of drug manufacturers in which massive financial buyouts are given to generic drugmakers while they wait to market their product, guaranteeing patent extensions. But is this legislation really necessary? Not according to some critics who say that it is in the best  interest of Pharma to invest in next-generation research and development, as such buyouts targeted by the legislature in this case are “last-ditch” efforts by some manufacturers to stifle generic competition. | LINK

Related Posts Within Doctor Pundit:

1. MN Legislator’s Bill Would Extended Pharma Disclosure Provision to Device Companies These days, professionals in healthcare have learned to accept the...
2. Report: Pharma Amplified Global H1N1 Scare What is known about the H1N1 epidemic that plagued the...
3. SCOTUS Rules on a Couple of Important Pharma Cases Clarence Thomas wrote for the 5-4 decision in which companies...
4. Pharma Company Strives to Keep Star Performing Drug Close Twenty-eleven and 2012 are going to be remembered in the...
5. Pfizer’s Game Plan Critiqued As a follow-up to a DP post on the unusual...